BCL2L14 (BCL2 like 14) is a pro-apoptotic gene that plays a multifaceted role in apoptosis regulation and disease pathogenesis. Functionally, BCL2L14 promotes apoptotic processes through protein-protein interactions and kinase binding mechanisms 1. The gene has emerged as a critical player in several malignancies and inflammatory conditions. In triple-negative breast cancer (TNBC), BCL2L14-ETV6 fusion proteins drive aggressive disease phenotypes, enhancing cell motility and invasiveness while promoting epithelial-mesenchymal transition and paclitaxel resistance 12. BCL2L14-ETV6 fusions are detected in 4.4-12.2% of TNBC tumors, predominantly in mesenchymal subtypes, making it a potential therapeutic target 1. Beyond cancer, BCL2L14 expression is epigenetically regulated in lupus nephritis, where increased BCL2L14 expression in CD4+ T cells promotes renal fibrosis and inflammation through Tfh cell differentiation modulation 3. BCL2L14 has also been identified as a methylation-regulated biomarker in necrotizing enterocolitis and nonobstructive azoospermia, diseases involving pathological programmed cell death 45. Curcumin treatment significantly alters BCL2L14 expression in glioblastoma cells, supporting its involvement in chemotherapy-induced apoptosis 6. These findings position BCL2L14 as both a disease biomarker and potential therapeutic target across multiple pathologies.